Venlaxafine-Associated Hepatitis
Authors: Yves Horsmans
Journal: Annals of Internal Medicine (1999)

Letters1 June 1999Venlaxafine-Associated HepatitisYves Horsmans, MD, Michel De Clercq, MD, and Christine Sempoux, MDYves Horsmans, MDCliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Horsmans)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (De Clercq)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Sempoux), Michel De Clercq, MDCliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Horsmans)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (De Clercq)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Sempoux), and Christine Sempoux, MDCliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Horsmans)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (De Clercq)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Sempoux)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-11-199906010-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Venlafaxine is a second-generation antidepressant agent approved for use in the United States in 1993 (1, 2). It is a derivative of phenethylanine and is structurally unrelated to first- and other second-generation antidepressant agents. Elevations of liver enzyme levels has rarely been described (2). We report the first case of acute hepatitis after venlafaxine administration.A 44-year-old woman was seen for acute hepatitis on 23 March 1998. Results of liver function tests done in September 1997 at the time of the introduction of venlafaxine therapy (150 mg/d) were normal. For several months the patient had also been ...References1. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49:280-94. CrossrefMedlineGoogle Scholar2. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother. 1995;29:387-95. CrossrefMedlineGoogle Scholar3. Johnson H, Bouman WP, Lawton J. Withdrawal reaction associated with venlafaxine. BMJ. 1998;317:787. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Yves Horsmans, MD; Michel De Clercq, MD; Christine Sempoux, MDAffiliations: Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Horsmans)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (De Clercq)Cliniques Universitaires Saint Luc; 1200 Brussels, Belgium (Sempoux) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEpinephrine and Outcome after Cardiac Arrest Paul E. Gause Epinephrine and Outcome after Cardiac Arrest Fritz Sterz , Wilhelm Behringer , and Harald Kittler Venlafaxine-Associated Hepatitis Xavier Cardona , Asunción Avila , and Pere Castellanos Metrics Cited byNarrative review of migraine management in patients with renal or hepatic diseaseEffects of the Antidepressants Citalopram and Venlafaxine on the Big Ramshorn Snail (Planorbarius corneus)Early intervention of acute liver injury related to venlafaxineDrug-Induced Liver InjuryClinical Impact of Depression in CirrhosisDrugs and ToxinsPsychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicityVenlafaxine and desvenlafaxineHepatotoxicity of Psychotropic Drugs and Drugs of AbuseVenlafaxine-induced Cholestatic HepatitisHepatic injury due to drugs, herbal compounds, chemicals and toxinsDrug-Induced Liver InjuryFulminant Hepatic Failure Induced by Venlafaxine and Trazodone Therapy: A Case ReportVenlafaxine-Induced Hepatotoxicity in a Patient with Ulcerative ColitisPharmacokinetic Changes of Psychotropic Drugs in Patients with Liver DiseaseReview of Duloxetine and Venlafaxine in DepressionANTIDEPRESSANTSPneumonitis Related to VenlafaxineAnswers to the Most Common Questions About the Hepatic Safety Profile of DuloxetineAntidepressant-lnduced Liver InjuryHepatitis Associated with Low-Dose Venlafaxine for Postmenopausal Vasomotor SymptomsVenlafaxineAdverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugsFatal Venlafaxine Overdose With Acinar Zone 3 Liver Cell NecrosisLow-dose venlafaxine-associated liver toxicity in chronic hepatitisTreatment of Anxiety and Depression in Transplant PatientsHepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactionsHepatic injury and pancreatitis during treatment with serotonin reuptake inhibitorsAntidepressant-induced hepatotoxicityComprehensive Review of Hepatitis C for Psychiatrists: Risks, Screening, Diagnosis, Treatment, and Interferon-Based Therapy ComplicationsProspective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugsAntidepressant drugsThe use of psychotropics in the medically illVenlafaxine-Associated HepatitisXavier Cardona, Asunción Avila, and Pere Castellanos 1 June 1999Volume 130, Issue 11Page: 944KeywordsBiopsyHepatitisHepatitis AHysterectomyInflammationLiverLiver function testsNecrosisSerum glutamic oxaloacetic transaminaseUltrasound imaging ePublished: 15 August 2000 Issue Published: 1 June 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...